napsgear semaglutide SpaDerma | | Tirzepatide Semaglutide: Half of Users Stop
Description
Research shows that most patients who experience tirzepatide-related headaches report improvement within 2 to 4 weeks as their bodies establish a new equilibrium
Supporting this, in a phase 2a trial in people with MASLD, the dual GLP-1/GCG agonist efinopegdutide (10 mg) reduced liver fat by 72.7%, compared to 42.3% with semaglutide (1 mg) despite similar WLindicating potential weight-independent effects of GCG on hepatic steatosis [40]
doi: 10.2337/dc08-1355
Sjgrens syndrome
